Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 15/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.32 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.32 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.32 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.32 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29957011 | 0.90 | CA1 (0.38) | PDK2APEX1PGRCYP1A2CYP2C19 | |
| SCHEMBL430235 | 0.90 | CA1 (0.38) | PDK2APEX1PGRCYP1A2CYP2C19 | |
| SCHEMBL16632979 | 0.88 | APEX1 (0.41) | PDK2APEX1PGRPCSK9ORAI1 | |
| SCHEMBL16633883 | 0.85 | APEX1 (0.40) | PDK2APEX1CYP2C19PCSK9 | |
| SCHEMBL16632924 | 0.84 | PDK2 (0.39) | PDK2APEX1PCSK9 | |
| SCHEMBL16633971 | 0.83 | PDK2 (0.40) | PDK2APEX1PCSK9 | |
| SCHEMBL10018630 | 0.79 | APEX1 (0.33) | PDK2APEX1PGR | |
| SCHEMBL1271141 | 0.79 | APEX1 (0.41) | PDK2APEX1PGRCYP1A2CYP2C19 | |
| SCHEMBL1394829 | 0.78 | APEX1 (0.47) | PDK2APEX1PGRCYP1A2CYP2C19 | |
| SCHEMBL29484836 | 0.78 | APEX1 (0.47) | PDK2APEX1PGRCYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2886548-A1 | METHOD FOR PRODUCING BORINIC ACID DERIVATIVE, AND NOVEL BORINIC ACID DERIVATIVE | Manac Inc. (JP) | 2015-06-24 | — | — | EP | disclosed |
| US-20150105562-A1 | METHOD FOR PREPARING BORINIC ACID DERIVATIVES AND NOVEL BORINIC ACID DERIVATIVES | MANAC INC. (JP) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105562-A1 | METHOD FOR PREPARING BORINIC ACID DERIVATIVES AND NOVEL BORINIC ACID DERIVATIVES | ADORA2B, TPSAB1, ACVR2B | PDK2 2287/4885APEX1 551/4885PGR 2131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.